Skinvisible, Inc. (SKVI)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Skinvisible, Inc. (SKVI) trades at $0.21. Skinvisible, Inc. develops and sells topical, transdermal, and mucosal polymer-based delivery system technologies. Market cap: $1.15M, Sector: Consumer defensive.
Last analyzed: Mar 17, 2026Analyst Coverage for SKVI: SKVI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SKVI against Consumer Defensive peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SKVI: 1/1 perspectives are bearish.
Skinvisible, Inc. (SKVI) Consumer Business Overview
Skinvisible, Inc. focuses on topical delivery system technologies, offering solutions for pharmaceutical, skincare, and cosmetic industries. With its Invisicare technology, the company reformulates existing products and develops new formulations. Operating in the consumer defensive sector, Skinvisible licenses its technology and sells products under the Skinbrella brand.
What Is the Investment Thesis for SKVI?
Skinvisible, Inc. presents a unique investment proposition within the consumer defensive sector, driven by its proprietary Invisicare technology. The company's ability to reformulate existing pharmaceutical products and create new formulations for skincare and cosmetics offers significant growth potential. With a gross margin of 100.0%, Skinvisible demonstrates the value of its technology. Key catalysts include expanding licensing agreements and successful reformulation projects. However, the company's negative P/E ratio of -2.31 and a substantial negative profit margin of -2454.5% indicate financial challenges. The company's small size, with only 2 employees, and its OTC listing introduce additional risks. The beta of 1.60 suggests higher volatility compared to the market. Investors should carefully consider these factors when evaluating Skinvisible's potential.
Based on FMP financials and quantitative analysis
SKVI Key Highlights
- Gross margin of 100.0% indicates strong pricing power and efficient production.
- Beta of 1.60 suggests higher volatility compared to the market average.
- Focus on polymer-based delivery systems provides a niche in the pharmaceutical and cosmetic industries.
- Invisicare technology offers potential for licensing and reformulation revenue streams.
- Market capitalization of $0.00B reflects the company's small size and early stage of development.
Who Are SKVI's Competitors?
SKVI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CMGHF Chaoda Modern Agriculture (Holdings) Limited | $0.04 | +0.00% | $5.90M | 40 |
| FACYF Fancl Corporation | $17.45 | +0.00% | $2.37B | 63 |
| SGI Somnigroup International Inc | $72.67 | +0.48% | $15.28B | 62 |
| ELF e.l.f. Beauty, Inc. | $61.15 | +0.77% | 4B | 59 |
| MIOFF Milbon Co., Ltd. | $52.60 | +0.00% | $1.71B | 58 |
| KCDMF Kimberly-Clark de México, S. A. B. de C. V. | $2.10 | -3.67% | $6.30B | 48 |
| KCDMY Kimberly-Clark de México, S. A. B. de C. V. | $10.66 | +4.00% | $6.41B | 48 |
| PG The Procter & Gamble Company | $149.61 | +0.86% | $348.38B | 48 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SKVI's Key Strengths?
- Proprietary Invisicare technology.
- Expertise in topical drug delivery systems.
- Potential for licensing and reformulation revenue.
- High gross margin of 100.0%.
What Are SKVI's Weaknesses?
- Small company size with only 2 employees.
- Negative P/E ratio and profit margin.
- Limited brand recognition.
- OTC listing introduces additional risks.
What Could Drive SKVI Stock Higher?
- Potential new licensing agreements for Invisicare technology.
- Successful reformulation of off-patent pharmaceutical products.
- Expansion of the Skinbrella product line.
- Development of new skincare and cosmetic formulations.
- Exploration of non-dermatological applications for Invisicare.
What Are the Key Risks for SKVI?
- Limited financial disclosure due to OTC Other listing.
- Low trading volume and wide bid-ask spreads.
- Competition from established players in the pharmaceutical and cosmetic industries.
- Dependence on a small number of licensing agreements for revenue.
- Regulatory hurdles for new drug formulations.
What Are the Growth Opportunities for SKVI?
- Expanding licensing agreements for Invisicare technology: Skinvisible's core growth strategy revolves around expanding the licensing of its Invisicare technology to pharmaceutical and consumer goods companies. The global drug delivery market is projected to reach $237 billion by 2026, presenting a significant opportunity for Skinvisible to capitalize on its proprietary technology. Securing additional licensing agreements would provide a recurring revenue stream and validate the market demand for Invisicare. The timeline for realizing this growth opportunity is ongoing, with continuous efforts to engage potential partners and showcase the benefits of Invisicare.
- Reformulating off-patent pharmaceutical products: Skinvisible offers pharmaceutical companies a solution to extend the lifecycle of their products by reformulating off-patent drugs with new Invisicare patents. The market for reformulated drugs is substantial, as pharmaceutical companies seek to maintain market share and revenue streams. Skinvisible's ability to provide new product benefits and line extensions through its technology positions it as a valuable partner for pharmaceutical companies. The timeline for this growth opportunity is dependent on the number of off-patent drugs and the willingness of pharmaceutical companies to invest in reformulation efforts.
- Developing new skincare and cosmetic formulations: Skinvisible's Invisicare technology can be applied to develop innovative skincare and cosmetic formulations. The global skincare market is projected to reach $180 billion by 2027, driven by increasing consumer demand for anti-aging, sun protection, and moisturizing products. Skinvisible can leverage its technology to create unique formulations with enhanced delivery and efficacy, targeting specific skincare concerns. The timeline for this growth opportunity depends on the company's ability to develop and market successful skincare and cosmetic products.
- Expanding the Skinbrella product line: Skinvisible markets sunless tanning and sunscreen products under the Skinbrella brand. The global sun care market is projected to reach $16.78 billion by 2028, driven by increasing awareness of the harmful effects of sun exposure. Skinvisible can expand its Skinbrella product line to capture a larger share of this market. This includes developing new formulations, expanding distribution channels, and increasing marketing efforts. The timeline for this growth opportunity is dependent on the company's ability to effectively compete with established players in the sun care market.
- Exploring non-dermatological applications: Skinvisible's Invisicare technology has potential applications beyond dermatology, including women's health and pain management. The market for women's health products is substantial, driven by increasing demand for solutions to address menopause, fertility, and other health concerns. Similarly, the pain management market is growing, driven by the aging population and the increasing prevalence of chronic pain conditions. Skinvisible can explore these non-dermatological applications to diversify its revenue streams and expand its market reach. The timeline for this growth opportunity depends on the company's ability to develop and commercialize new formulations for these markets.
What Opportunities Does SKVI Have?
- Expanding licensing agreements with pharmaceutical companies.
- Reformulating off-patent drugs with new Invisicare patents.
- Developing new skincare and cosmetic formulations.
- Expanding the Skinbrella product line.
What Threats Does SKVI Face?
- Competition from established players in the pharmaceutical and cosmetic industries.
- Regulatory hurdles for new drug formulations.
- Potential for technological obsolescence.
- Economic downturn affecting consumer spending on personal care products.
What Are SKVI's Competitive Advantages?
- Proprietary Invisicare technology provides a competitive advantage in drug delivery.
- Expertise in polymer-based formulations for topical, transdermal, and mucosal applications.
- Established relationships with pharmaceutical and consumer goods companies.
- Ability to reformulate off-patent drugs and create new product benefits.
What Does SKVI Do?
Skinvisible, Inc., established in 1998 and based in Las Vegas, Nevada, specializes in the development, manufacture, and sale of polymer-based delivery system technologies. Originally named Microbial Solutions, Inc., the company rebranded in 1999 to reflect its focus on skin-related applications. Skinvisible's core business revolves around its Invisicare technology, which enables the creation of topical, transdermal, and mucosal formulations for various markets, including pharmaceutical, over-the-counter (OTC), personal skincare, and cosmetics. The company's product offerings extend beyond dermatological applications, encompassing solutions for women's health, pain management, and other therapeutic areas. Skinvisible markets sunless tanning and sunscreen products under the Skinbrella brand. A key aspect of Skinvisible's business model is licensing its Invisicare technology to pharmaceutical and consumer goods companies. The company also assists pharmaceutical clients in the early stages of formulation development. Furthermore, Skinvisible provides solutions to pharmaceutical companies by reformulating their off-patent products with new Invisicare patents, thereby creating new product benefits and line extensions. This approach allows pharmaceutical companies to extend the lifecycle of their products and maintain a competitive edge.
What Products and Services Does SKVI Offer?
- Develops topical, transdermal, and mucosal polymer-based delivery system technologies.
- Manufactures and sells formulations for pharmaceutical, over-the-counter, personal skincare, and cosmetic markets.
- Offers solutions for women's health, pain management, and other markets.
- Provides sunless tanning and sunscreen products under the Skinbrella brand.
- Licenses Invisicare technology to pharmaceutical and consumer goods companies.
- Assists pharmaceutical clients in the early development of formulations.
- Reformulates off-patent pharmaceutical products with new Invisicare patents.
How Does SKVI Make Money?
- Licensing Invisicare technology to pharmaceutical and consumer goods companies.
- Selling sunless tanning and sunscreen products under the Skinbrella brand.
- Providing formulation development services to pharmaceutical clients.
- Reformulating off-patent pharmaceutical products with new Invisicare patents.
What Industry Does SKVI Operate In?
Skinvisible, Inc. operates within the household and personal products industry, a segment of the broader consumer defensive sector. This industry is characterized by relatively stable demand, as consumers continue to purchase essential personal care items regardless of economic conditions. The market is highly competitive, with established players like ASCC, BABYF, CMGHF, DRNK, and HRSR dominating shelf space and consumer mindshare. Skinvisible differentiates itself through its Invisicare technology, which offers unique delivery system solutions for pharmaceutical and cosmetic applications. The company's success depends on its ability to secure licensing agreements and penetrate established markets with its innovative formulations.
Who Are SKVI's Key Customers?
- Pharmaceutical companies seeking to reformulate off-patent drugs.
- Consumer goods companies looking to incorporate advanced delivery systems into their products.
- Consumers seeking sunless tanning and sunscreen products.
- Pharmaceutical companies seeking assistance in early-stage formulation development.
SKVI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Skinvisible's growth potential, indicating that those with the most knowledge about the company believe in its future.
- Community sentiment has shifted positively due to recent product launches, generating excitement among consumers and investors alike.
- The company's innovative approach to skincare has garnered attention, positioning it well in a competitive market focused on health and wellness.
- Social media discussions highlight a growing interest in Skinvisible's unique formulations, reflecting a potential increase in consumer demand.
Bear Case
- Concerns over the company's ability to scale production effectively have been echoed in recent community discussions, raising doubts about meeting potential demand.
- Recent negative reviews on social platforms have sparked debate about product efficacy, which could impact brand reputation and sales.
- Market perception remains cautious due to the competitive landscape, with established brands dominating consumer trust and loyalty.
- Insider selling activity has raised eyebrows, leading to speculation about potential challenges ahead that could hinder company performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SKVI Latest News
-
Stocks That Hit 52-Week Highs On Tuesday
· Mar 24, 2020
-
Stocks That Hit 52-Week Lows On Thursday
· Oct 10, 2019
SKVI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SKVI.
Price Targets
Wall Street price target analysis for SKVI.
SKVI MoonshotScore
What does this score mean?
The MoonshotScore rates SKVI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Terry H. Howlett
CEO
Terry H. Howlett serves as the CEO of Skinvisible, Inc., leading a small team of 2 employees. Information regarding his detailed career history, education, and previous roles is not available in the provided data. However, as the CEO, he is responsible for the overall strategic direction and operational management of the company. His leadership is crucial in driving the adoption of Skinvisible's Invisicare technology and expanding its market reach.
Track Record: Due to the limited information available, it is difficult to assess Terry H. Howlett's specific achievements and strategic decisions as CEO. However, his leadership is essential in navigating the challenges of a small, OTC-listed company and capitalizing on the opportunities presented by Skinvisible's proprietary technology. Further information is needed to evaluate his track record and contributions to the company's growth and development.
SKVI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often lack stringent listing requirements, leading to increased risk and potential for speculative trading. Investing in OTC Other stocks requires a higher degree of due diligence and risk tolerance.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure due to OTC Other listing.
- Potential for low trading volume and wide bid-ask spreads.
- Higher risk of fraud or manipulation compared to major exchanges.
- Limited regulatory oversight and investor protection.
- Dependence on a small number of licensing agreements for revenue.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the market demand for Skinvisible's Invisicare technology.
- Evaluate the company's competitive landscape and market positioning.
- Determine the company's cash flow and ability to fund future growth.
- Understand the terms of any licensing agreements and their potential impact on revenue.
- Consult with a qualified financial advisor before making any investment decisions.
- Proprietary Invisicare technology with potential applications in various markets.
- Existing licensing agreements with pharmaceutical and consumer goods companies.
- Focus on reformulating off-patent drugs to create new product benefits.
- High gross margin of 100.0% indicates strong pricing power.
- The company has been in operation since 1998.
Skinvisible, Inc. Consumer Defensive Stock: Key Questions Answered
What does Skinvisible, Inc. do?
Skinvisible, Inc. specializes in the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies. Their core technology, Invisicare, is used to create formulations for pharmaceutical, over-the-counter, personal skincare, and cosmetic markets. The company also offers solutions for women's health and pain management. Skinvisible generates revenue through licensing its Invisicare technology, selling Skinbrella-branded sunless tanning and sunscreen products, and providing formulation development services to pharmaceutical clients. Their business model focuses on leveraging their proprietary technology to create value for both pharmaceutical and consumer goods companies.
What do analysts say about SKVI stock?
As of 2026-03-17, there is no available analyst coverage for Skinvisible, Inc. (SKVI). The company's OTC listing and small market capitalization likely contribute to the lack of analyst attention. Key valuation metrics, such as P/E ratio (-2.31) and profit margin (-2454.5%), indicate financial challenges. Investors should conduct their own thorough research and consider the risks associated with investing in a small, OTC-listed company before making any investment decisions. The potential for growth through licensing and reformulation efforts should be weighed against the company's current financial performance and limited liquidity.
What are the main risks for SKVI?
Skinvisible, Inc. faces several risks, including its OTC Other listing, which results in limited financial disclosure and potential for low trading volume. The company's small size and negative profitability metrics also pose significant risks. Competition from established players in the pharmaceutical and cosmetic industries could hinder Skinvisible's ability to gain market share. Dependence on a small number of licensing agreements for revenue creates vulnerability. Regulatory hurdles for new drug formulations and potential technological obsolescence also represent ongoing risks for the company. Investors should carefully consider these risks before investing in SKVI.
What are the key factors to evaluate for SKVI?
Evaluate SKVI on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does SKVI data refresh on this page?
SKVI prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SKVI's recent stock price performance?
Skinvisible, Inc. (SKVI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Invisicare technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SKVI overvalued or undervalued right now?
Valuing Skinvisible, Inc. (SKVI) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying SKVI?
Before investing in Skinvisible, Inc. (SKVI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available for OTC-listed companies.
- Financial data may not be fully up-to-date.
- AI analysis pending for SKVI.